Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

International Journal of Obesity

Volumn 38, Issue 6, 2014, Pages 784-793

  Van Can, J ^a   Sloth, B ^b   Jensen, C B ^b   Flint, A ^b   Blaak, E E ^a   Saris, W H M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NOVO NORDISK A S   (Denmark)

Author keywords

energy expenditure; energy intake; postprandial glucose; substrate oxidation; weight management

Indexed keywords

C PEPTIDE; CARBON DIOXIDE; GLUCAGON; GLUCOSE; INSULIN; LIRAGLUTIDE; PARACETAMOL; PARACETAMOL 500PCH; PLACEBO; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; APPETITE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; EVENING DOSAGE; FEMALE; FOOD INTAKE; GAS EXCHANGE; GASTROINTESTINAL DISEASE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART RATE; HUMAN; HUNGER; INSULIN BLOOD LEVEL; INSULIN INJECTION PEN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; METABOLIC RATE; NAUSEA; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN URINE LEVEL; OBESITY; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; RESTING ENERGY EXPENDITURE; RESTING METABOLIC RATE; RISK ASSESSMENT; SATIETY; SIDE EFFECT; SINGLE DRUG DOSE; SLEEPING ENERGY EXPENDITURE; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; TEST MEAL; THERAPY EFFECT; THIRST; THROMBOSIS; TOE THROMBOSIS; TOOTH INFECTION; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY EXCRETION; VISUAL ANALOG SCALE; WEIGHT CHANGE; WEIGHT REDUCTION; WELLBEING; ADOLESCENT; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; APPETITE; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; SATIATION; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84902254986     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.162     Document Type: Article

References (40)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
3. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-1211.
4. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE et al. Glucagonlike peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452-458.
5. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
6. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25: 781-792.
7. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
8. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.
9. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
10. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011; 36: 843-854.
11. Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther 2011; 28: 650-660.
12. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97: 258-266.
13. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagonlike peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011; 28: 213-226.
14. Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl 2010; 167: 35-43.
15. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Last amended by the 59th WMA Assembly, Seoul. Oct-2008. JAMA 2000; 284: 3043-3045.
16. ICH Harmonised Tripartite Guideline. International Conference on Harmonisation 1996http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/ Efficacy/E6-R1/Step4/E6-R1-Guideline.pdfAccessed 14 Nov 2012.
17. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
18. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001; 46: 2256-2262.
19. Sanaka M, Kuyama Y, Yamanaka M. Guide for judicious use of the paracetamol absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 1998; 33: 785-791.
20. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assesment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000; 24: 38-48.
21. Schoffelen PF, Westerterp KR, Saris WH, Ten HF. A dual-respiration chamber system with automated calibration. J Appl Physiol 1997; 83: 2064-2072.
22. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1-9.
23. Frayn KN. Calculation of substrate oxidation rates in-vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
24. Westerterp Kr, Wilson SA, Rolland V. Diet induced thermogenesis measured over 24h in a respiration chamber: effect of diet composition. Int J Obes Relat Metab Disord 1999; 23: 287-292.
25. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 1986; 78: 1568-1578.
26. Human energy requirements. Report of a joint FAO/WHO/UNU expert consultation. FAO: food and nutrition technical report series 1. FAO/WHO/UNU 2004.
27. Schrauwen P, van Marken Lichtenbelt WD, Westerterp KR. Energy balance in a respiration chamber: individual adjustment of energy intake to energy expenditure. Int J Obes Relat Metab Disord 1997; 21: 769-774.
28. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
29. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl 3): 26-34.
30. Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab 2013; 15: 958-962.
31. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
32. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113-119.
33. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-1921.
34. Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care 2012; 35: 4-11.
35. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 2012; 37: 893-899.
36. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009; 43: 1433-1444.
37. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2009; 373: 473-481.
38. Devries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454.
39. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase in patients using GLP-1 receptor agonists or DPP-4 inhibitors in the outpatient setting. Endocr Pract 2012; 18: 1-16.
40. Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr 2000; 71: 1421-1432.